Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 76

1.

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.

Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR; CTD-ILD Special Interest Group.

Thorax. 2014 May;69(5):428-36. doi: 10.1136/thoraxjnl-2013-204202. Epub 2013 Dec 24. Erratum in: Thorax. 2014 Sep;69(9):834. CTD-ILD Special Interest Group [added]; multiple investigator names added.

2.

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.

Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D; ATS/ERS Committee on Idiopathic Interstitial Pneumonias.

Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48. doi: 10.1164/rccm.201308-1483ST.

3.

Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide.

Cremers JP, Drent M, Bast A, Shigemitsu H, Baughman RP, Valeyre D, Sweiss NJ, Jansen TL.

Curr Opin Pulm Med. 2013 Sep;19(5):545-61. doi: 10.1097/MCP.0b013e3283642a7a. Review.

PMID:
23880702
4.

Ten misconceptions about antioxidants.

Bast A, Haenen GR.

Trends Pharmacol Sci. 2013 Aug;34(8):430-6. doi: 10.1016/j.tips.2013.05.010. Epub 2013 Jun 24. Review.

PMID:
23806765
5.

Methotrexate vs azathioprine in second-line therapy of sarcoidosis.

Vorselaars ADM, Wuyts WA, Vorselaars VMM, Zanen P, Deneer VHM, Veltkamp M, Thomeer M, van Moorsel CHM, Grutters JC.

Chest. 2013 Sep;144(3):805-812. doi: 10.1378/chest.12-1728.

PMID:
23538719
6.

Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis.

Mostard RL, Verschakelen JA, van Kroonenburgh MJ, Nelemans PJ, Wijnen PA, Vöö S, Drent M.

Respir Med. 2013 Mar;107(3):439-47. doi: 10.1016/j.rmed.2012.11.011. Epub 2012 Dec 19.

7.

Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A.

Mol Med. 2012 Nov 15;18:1430-6. doi: 10.2119/molmed.2012.00332.

8.

The pathogenesis of pulmonary fibrosis: a moving target.

Wuyts WA, Agostini C, Antoniou KM, Bouros D, Chambers RC, Cottin V, Egan JJ, Lambrecht BN, Lories R, Parfrey H, Prasse A, Robalo-Cordeiro C, Verbeken E, Verschakelen JA, Wells AU, Verleden GM.

Eur Respir J. 2013 May;41(5):1207-18. doi: 10.1183/09031936.00073012. Epub 2012 Oct 25. Review.

9.

Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good.

Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L; European IPF Consensus Group.

Thorax. 2012 Nov;67(11):938-40. doi: 10.1136/thoraxjnl-2012-202580. Epub 2012 Oct 9. No abstract available.

PMID:
23047830
10.

Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.

Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, Rosenfeld L, Mitiku TY, Cooper JM, Mehta D, Greenspon AJ, Ortman M, Delurgio DB, Valadri R, Narasimhan C, Swapna N, Singh JP, Danik S, Markowitz SM, Almquist AK, Krahn AD, Wolfe LG, Feinstein S, Ellenbogen KA.

Europace. 2013 Mar;15(3):347-54. doi: 10.1093/europace/eus316. Epub 2012 Sep 21.

PMID:
23002195
11.

Global burden of chronic pulmonary aspergillosis complicating sarcoidosis.

Denning DW, Pleuvry A, Cole DC.

Eur Respir J. 2013 Mar;41(3):621-6. doi: 10.1183/09031936.00226911. Epub 2012 Jun 27.

12.

A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.

Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA; Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet).

Am J Respir Crit Care Med. 2012 Jul 1;186(1):88-95. doi: 10.1164/rccm.201202-0314OC. Epub 2012 May 3.

13.

An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease.

Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, Drent M, Haslam PL, Kim DS, Nagai S, Rottoli P, Saltini C, Selman M, Strange C, Wood B; American Thoracic Society Committee on BAL in Interstitial Lung Disease.

Am J Respir Crit Care Med. 2012 May 1;185(9):1004-14. doi: 10.1164/rccm.201202-0320ST.

PMID:
22550210
14.

Therapy for sarcoidosis: evidence-based recommendations.

Baughman RP, Nunes H.

Expert Rev Clin Immunol. 2012 Jan;8(1):95-103. doi: 10.1586/eci.11.84. Review.

PMID:
22149344
15.

Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis.

Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M.

Graefes Arch Clin Exp Ophthalmol. 2012 May;250(5):713-20. doi: 10.1007/s00417-011-1844-0. Epub 2011 Nov 27.

16.

Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis.

Mostard RL, Vöö S, van Kroonenburgh MJ, Verschakelen JA, Wijnen PA, Nelemans PJ, Erckens RJ, Drent M.

Respir Med. 2011 Dec;105(12):1917-24. doi: 10.1016/j.rmed.2011.08.012. Epub 2011 Sep 6.

17.

Sarcoidosis diagnosed after September 11, 2001, among adults exposed to the World Trade Center disaster.

Jordan HT, Stellman SD, Prezant D, Teirstein A, Osahan SS, Cone JE.

J Occup Environ Med. 2011 Sep;53(9):966-74. doi: 10.1097/JOM.0b013e31822a3596.

PMID:
21860326
18.

How to diagnose and manage difficult problems of calcium metabolism in sarcoidosis: an evidence-based review.

Vucinic V, Skodric-Trifunovic V, Ignjatović S.

Curr Opin Pulm Med. 2011 Sep;17(5):297-302. doi: 10.1097/MCP.0b013e328348b3cb. Review.

PMID:
21832916
19.

Type D or 'distressed' personality in sarcoidosis and idiopathic pulmonary fibrosis.

Elfferich MD, De Vries J, Drent M.

Sarcoidosis Vasc Diffuse Lung Dis. 2011 Jul;28(1):65-71.

PMID:
21796893
20.

Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force.

Baughman RP, Nagai S, Balter M, Costabel U, Drent M, du Bois R, Grutters JC, Judson MA, Lambiri I, Lower EE, Muller-Quernheim J, Prasse A, Rizzato G, Rottoli P, Spagnolo P, Teirstein A.

Sarcoidosis Vasc Diffuse Lung Dis. 2011 Jul;28(1):56-64.

PMID:
21796892

Supplemental Content

Loading ...
Support Center